Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in China, has announced its financial results for 2023. The company reported revenues of RMB 1.503 billion (USD 208 million), an increase of 3.38% year-on-year (YOY), primarily driven by sales of its commercialized products. During the year, Junshi’s COVID-19 therapy, Mindewei (deuremidevir), was included in the National Reimbursement Drug List (NRDL), and its programmed death-1 (PD-1) inhibitor, Loqtorzi (toripalimab), received marketing approval in the United States.
In October 2023, toripalimab was granted marketing approval in the US for two indications: first-line treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) combined with chemotherapy, and for recurrent, unresectable, or metastatic NPC that has progressed during or after chemotherapy alone.
Additionally, tifcemalimab (anti-BTLA) initiated two Phase III clinical studies, with the first patient enrollment completed in China, the US, and Europe. The company’s PCSK9 monoclonal antibody (mAb), ongericimab, is awaiting a regulatory decision, while JS005 (IL-17A) is in a Phase III study for psoriasis. Junshi’s pipeline includes a range of other products such as the Claudin18.2-targeted antibody drug conjugate (ADC) JS107, the small molecule PI3K-α inhibitor JS105, the siRNA drug targeting ANGPTL3 JS401, the anti-CGRP monoclonal antibody JS010, the CD20/CD3 bispecific antibody (BsAb) JS203, the PD-1/VEGF BsAb JS207, and the subcutaneous PD-1 monoclonal antibody injection JS001sc.- Flcube.com
